CD123 and its potential clinical application in leukemias-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

CD123 and its potential clinical application in leukemias

Published:2015-02 Issue: Volume:122 Page:59-64
ISSN:0024-3205
Container-title:Life Sciences
language:en
Short-container-title:Life Sciences

Author:

Liu Keqiang,Zhu Mengru,Huang Yao,Wei Shuhua,Xie Jingli,Xiao Yechen

Funder

National Natural Science Foundation of China

Jilin Provincial Science & Technology Department

Publisher

Elsevier BV

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference73 articles.

1. ScFv antibody: principles and clinical application;Ahmad;Clin. Dev. Immunol.,2012

2. In vitro interleukin-3 binding to leukemia cells predicts cytotoxicity of a diphtheria toxin/IL-3 fusion protein;Alexander;Bioconjug. Chem.,2000

3. Roles of the N and C terminal domains of the interleukin-3 receptor α chain in receptor function;Barry;Blood,1997

4. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL);Bassan;Blood,2009

5. Diphtheria toxin-interleukin-3 fusion protein (DT388IL3) prolongs disease-free survival of leukemic immunocompromised mice;Black;Leukemia,2003

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recent advances in CAR‐T cell therapy for acute myeloid leukaemia;Journal of Cellular and Molecular Medicine;2024-05

2. Dual-targeting CD33/CD123 NANOBODY T-cell engager with potent anti-AML activity and good safety profile;Blood Advances;2024-04-26

3. EP300-ZNF384 transactivates IL3RA to promote the progression of B-cell acute lymphoblastic leukemia;Cell Communication and Signaling;2024-04-02

4. Targeting signaling pathways in cancer stem cells: A potential approach for developing novel anti-cancer therapeutics;International Review of Cell and Molecular Biology;2024

5. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia;Blood Advances;2023-10-26

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3